Literature DB >> 22262078

GLP-1, the gut-brain, and brain-periphery axes.

Cendrine Cabou1, Rémy Burcelin.   

Abstract

Glucagon-like peptide 1 (GLP-1) is a gut hormone which directly binds to the GLP-1 receptor located at the surface of the pancreatic β-cells to enhance glucose-induced insulin secretion. In addition to its pancreatic effects, GLP-1 can induce metabolic actions by interacting with its receptors expressed on nerve cells in the gut and the brain. GLP-1 can also be considered as a neuropeptide synthesized by neuronal cells in the brain stem that release the peptide directly into the hypothalamus. In this environment, GLP-1 is assumed to control numerous metabolic and cardiovascular functions such as insulin secretion, glucose production and utilization, and arterial blood flow. However, the exact roles of these two locations in the regulation of glucose homeostasis are not well understood. In this review, we highlight the latest experimental data supporting the role of the gut-brain and brain-periphery axes in the control of glucose homeostasis. We also focus our attention on the relevance of β-cell and brain cell targeting by gut GLP-1 for the regulation of glucose homeostasis. In addition to its action on β-cells, we find that understanding the physiological role of GLP-1 will help to develop GLP-1-based therapies to control glycemia in type 2 diabetes by triggering the gut-brain axis or the brain directly. This pleiotropic action of GLP-1 is an important concept that may help to explain the observation that, during their treatment, type 2 diabetic patients can be identified as 'responders' and 'non-responders'.
Copyright © by Lab & Life Press/SBDR

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22262078      PMCID: PMC3280675          DOI: 10.1900/RDS.2011.8.418

Source DB:  PubMed          Journal:  Rev Diabet Stud        ISSN: 1613-6071


  113 in total

1.  Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene.

Authors:  L A Scrocchi; T J Brown; N MaClusky; P L Brubaker; A B Auerbach; A L Joyner; D J Drucker
Journal:  Nat Med       Date:  1996-11       Impact factor: 53.440

2.  Effects of exenatide on systolic blood pressure in subjects with type 2 diabetes.

Authors:  Ted Okerson; Ping Yan; Anthony Stonehouse; Robert Brodows
Journal:  Am J Hypertens       Date:  2009-12-17       Impact factor: 2.689

3.  Molecular mechanisms underlying nutrient detection by incretin-secreting cells.

Authors:  Frank Reimann
Journal:  Int Dairy J       Date:  2010-04       Impact factor: 3.032

4.  Functional expression of the rat glucagon-like peptide-I receptor, evidence for coupling to both adenylyl cyclase and phospholipase-C.

Authors:  M B Wheeler; M Lu; J S Dillon; X H Leng; C Chen; A E Boyd
Journal:  Endocrinology       Date:  1993-07       Impact factor: 4.736

5.  Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets.

Authors:  Loredana Farilla; Angela Bulotta; Boaz Hirshberg; Sergio Li Calzi; Nasif Khoury; Houtan Noushmehr; Cristina Bertolotto; Umberto Di Mario; David M Harlan; Riccardo Perfetti
Journal:  Endocrinology       Date:  2003-08-28       Impact factor: 4.736

6.  Receptor gene expression of glucagon-like peptide-1, but not glucose-dependent insulinotropic polypeptide, in rat nodose ganglion cells.

Authors:  Atsushi Nakagawa; Hanae Satake; Hajime Nakabayashi; Makoto Nishizawa; Keisuke Furuya; Shigeru Nakano; Toshikazu Kigoshi; Kohzo Nakayama; Kenzo Uchida
Journal:  Auton Neurosci       Date:  2004-01-30       Impact factor: 3.145

7.  Expression cloning of the pancreatic beta cell receptor for the gluco-incretin hormone glucagon-like peptide 1.

Authors:  B Thorens
Journal:  Proc Natl Acad Sci U S A       Date:  1992-09-15       Impact factor: 11.205

8.  Effects of glucagon-like peptide-1, yohimbine, and nitrergic modulation on sympathetic and parasympathetic activity in humans.

Authors:  Adil E Bharucha; Nisha Charkoudian; Christopher N Andrews; Michael Camilleri; David Sletten; Alan R Zinsmeister; Phillip A Low
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2008-07-02       Impact factor: 3.619

9.  Characterisation of the processing by human neutral endopeptidase 24.11 of GLP-1(7-36) amide and comparison of the substrate specificity of the enzyme for other glucagon-like peptides.

Authors:  K Hupe-Sodmann; G P McGregor; R Bridenbaugh; R Göke; B Göke; H Thole; B Zimmermann; K Voigt
Journal:  Regul Pept       Date:  1995-08-22

10.  Arcuate glucagon-like peptide 1 receptors regulate glucose homeostasis but not food intake.

Authors:  Darleen A Sandoval; Didier Bagnol; Stephen C Woods; David A D'Alessio; Randy J Seeley
Journal:  Diabetes       Date:  2008-05-16       Impact factor: 9.461

View more
  28 in total

Review 1.  The continuing need for drug development and clinical trials in type 2 diabetes and its complications: introduction to the RDS special issue.

Authors:  Itamar Raz; Baptist Gallwitz
Journal:  Rev Diabet Stud       Date:  2011-11-10

2.  cAMP-independent effects of GLP-1 on β cells.

Authors:  Jelena Kolic; Patrick E MacDonald
Journal:  J Clin Invest       Date:  2015-11-16       Impact factor: 14.808

Review 3.  Neurochemical regulators of food behavior for pharmacological treatment of obesity: current status and future prospects.

Authors:  Gayane Sargis Vardanyan; Hasmik Samvel Harutyunyan; Michail Iosif Aghajanov; Ruben Sargis Vardanyan
Journal:  Future Med Chem       Date:  2020-10-12       Impact factor: 3.808

Review 4.  Gut-brain connection: The neuroprotective effects of the anti-diabetic drug liraglutide.

Authors:  Emanuel Monteiro Candeias; Inês Carolina Sebastião; Susana Maria Cardoso; Sónia Catarina Correia; Cristina Isabel Carvalho; Ana Isabel Plácido; Maria Sancha Santos; Catarina Resende Oliveira; Paula Isabel Moreira; Ana Isabel Duarte
Journal:  World J Diabetes       Date:  2015-06-25

5.  Glutathione peroxidase mimic ebselen improves glucose-stimulated insulin secretion in murine islets.

Authors:  Xinhui Wang; Jun-Won Yun; Xin Gen Lei
Journal:  Antioxid Redox Signal       Date:  2013-08-09       Impact factor: 8.401

6.  Sitagliptin and liraglutide reversed nigrostriatal degeneration of rodent brain in rotenone-induced Parkinson's disease.

Authors:  Ghada A Badawi; Mai A Abd El Fattah; Hala F Zaki; Moushira I El Sayed
Journal:  Inflammopharmacology       Date:  2017-03-04       Impact factor: 4.473

Review 7.  Therapeutic potential of α7 nicotinic acetylcholine receptor agonists to combat obesity, diabetes, and inflammation.

Authors:  Han Xie; Natesh Yepuri; Qinghe Meng; Ravi Dhawan; Colin A Leech; Oleg G Chepurny; George G Holz; Robert N Cooney
Journal:  Rev Endocr Metab Disord       Date:  2020-08-26       Impact factor: 6.514

Review 8.  Novel GLP-1 (Glucagon-Like Peptide-1) Analogues and Insulin in the Treatment for Alzheimer's Disease and Other Neurodegenerative Diseases.

Authors:  Valeria Calsolaro; Paul Edison
Journal:  CNS Drugs       Date:  2015-12       Impact factor: 5.749

Review 9.  Regulation of glucose homeostasis by GLP-1.

Authors:  Prashant Nadkarni; Oleg G Chepurny; George G Holz
Journal:  Prog Mol Biol Transl Sci       Date:  2014       Impact factor: 3.622

Review 10.  Dipeptidyl Peptidase (DPP)-IV Inhibitors with Antioxidant Potential Isolated from Natural Sources: A Novel Approach for the Management of Diabetes.

Authors:  Anand-Krishna Singh; Dhananjay Yadav; Neha Sharma; Jun-O Jin
Journal:  Pharmaceuticals (Basel)       Date:  2021-06-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.